FLASH
FLASH researchers are strongly represented at the International Liver Congress 2022
22 to 25 June, the FLASH team participates in the International Liver Congress 2022 in London, where more than 430 faculty specialists discuss the latest research, current developments, challenges, and the future of hepatology with 5000+ other international delegates.
Researchers from FLASH contributes with no less than two oral presentations at General session, posters, skill sessions, and participation in expert panels. Camilla Dalby Hansen will present results from the REDUCTION study and Mads Israelsen will present results from the Rifaximin study/GALA-RIF study – both oral presentations at the general sessions. In the REDUCTION study, Camilla Dalby Hansen found that by introducing LCHF diet to type 2 diabetics, it is possible to significantly reduce the HbA1C. In the Rifaximin study, Mads Israelsen found that Rifaximin-α can stop progression of scar tissue in the liver among patients with alcohol overuse.
This Rifaximin study has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement number 668031.
The REDUCTION study has received funding from Novo Nordisk Fonden under Grant Number NNF16OC0021038.